Compare MTLS & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTLS | ENTA |
|---|---|---|
| Founded | 1990 | 1995 |
| Country | Belgium | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 387.8M | 378.0M |
| IPO Year | 2014 | 2012 |
| Metric | MTLS | ENTA |
|---|---|---|
| Price | $7.02 | $13.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $20.40 |
| AVG Volume (30 Days) | 80.0K | ★ 195.9K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.93 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $102,814,000.00 |
| Revenue This Year | $6.38 | $7.76 |
| Revenue Next Year | $6.45 | N/A |
| P/E Ratio | $61.39 | ★ N/A |
| Revenue Growth | N/A | ★ 16.48 |
| 52 Week Low | $4.78 | $7.05 |
| 52 Week High | $7.50 | $17.15 |
| Indicator | MTLS | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 63.31 | 50.26 |
| Support Level | $6.36 | $13.47 |
| Resistance Level | $7.50 | $13.98 |
| Average True Range (ATR) | 0.21 | 0.67 |
| MACD | 0.06 | 0.05 |
| Stochastic Oscillator | 80.58 | 36.99 |
Materialise NV is a provider of 3D-printed medical devices and software and a pioneer in additive manufacturing software and services. The company operates through three principal segments: Materialise Software, Materialise Medical, and Materialise Manufacturing, with the Materialise Medical segment generating maximum revenue. The Materialise Medical segment develops and delivers medical software solutions, medical devices, and related products and services; the Materialise Software segment develops and delivers additive manufacturing software solutions and related services; and the Materialise Manufacturing segment delivers 3D-printed products and related services. The company generates maximum revenue from the United States of America.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.